LPCAT1、CPEB1 mRNA联合检测对非小细胞肺癌患者术后复发转移的预测价值

Predictive value of combined detection of LPCAT1 and CPEB1 mRNA for postoperative recurrence and metastasis in patients with nonsmall cell lung cancer

摘要

目的 探讨溶血磷脂酰胆碱酰基转移酶1（LPCAT1）、胞质多聚腺苷酸化结合蛋白1（CPEB1）mRNA联合检测对非小细胞肺癌（NSCLC）患者术后复发转移的预测价值。方法 选取于平顶山市第一人民医院接受根治性手术治疗的85例NSCLC患者,收集手术切除的癌组织、癌旁组织,根据术后1年是否发生复发转移将患者分为未复发转移组（54例）、复发转移组（31例）。检测LPCAT1、CPEB1 mRNA表达水平,分析二者与NSCLC临床病理特征及术后复发转移的关系。结果 癌组织中LPCAT1 mRNA表达水平明显高于癌旁组织,CPEB1 mRNA表达水平明显低于癌旁组织（P<0.05）;二者均与NSCLC TNM分期、淋巴结转移、分化程度有关（P<0.05）。复发转移组LPCAT1 mRNA表达水平明显高于未复发转移组,CPEB1 mRNA表达水平明显低于未复发转移组（P<0.05）。LPCAT1、CPEB1 mRNA联合检测预测NSCLC术后复发转移的AUC为0.884,优于各单项指标（P<0.05）。与低表达组相比,LPCAT1高表达组患者的术后复发转移风险升高,CPEB1高表达组患者的复发转移风险降低（P<0.05）。结论 癌组织中LPCAT1、CPEB1 mRNA表达水平均与NSCLC临床病理特征及术后复发转移密切相关,二者联合检测对NSCLC术后复发转移具有较高预测价值。

Abstract

Objective To investigate the predictive value of combined detection of lysophosphatidylcholine acyltransferase 1 (LPCAT1) and cytoplasmic polyadenylationelementbinding protein 1 (CPEB1) mRNA for postoperative recurrence and metastasis in patients with nonsmall cell lung cancer (NSCLC). Methods A total of 85 NSCLC patients who underwent radical surgery at the First People's Hospital of Pingdingshan City from June 2022 to June 2024 were selected. Cancer tissues and adjacent non-cancerous tissues were collected. The patients were devided into non-recurrence and non-metastasis group (54 cases) and recurrence and metastasis group (31 cases) based on whether recurrence or metastasis occurred within one year after surgery. The LPCAT1 mRNA and CPEB1 mRNA expression were detected and their correlations with clinicopathological characteristics and postoperative recurrence/metastasis were analyzed. Results The LPCAT1 mRNA expression in cancerous tissues was obviously higher than that in adjacent non-cancerous tissues, while the CPEB1 mRNA expression was significanly lower (P<0.05). both expvession levels were related to NSCLC TNM stage, lymph node metastasis, and differentiation degree (P<0.05). Compared with non-recurrence and non-metastasis group, the LPCAT1 mRNA expression was obviously higher, CPEB1 mRNA expression was obviously lower in recurrence and metastasis group (P<0.05). The AUC of the combined detection of LPCAT1 mRNA and CPEB1 mRNA for predicting postoperative recurrence and metastasis in NSCLC was 0.884, which was superior to that of each individual marker (P<0.05). Compared with the lowexpression group, the risk of postoperative recurrence and metastasis increased in LPCAT1 mRNA highexpression group, while the risk decreased in CPEB1 mRNA highexpression group (P<0.05). Conclusion The LPCAT1 mRNA and CPEB1 mRNA expression in cancerous tissues are all closely related to pathological characteristics and postoperative recurrence and metastasis of NSCLC, and combined detection of these two has high predictive value for postoperative recurrence and metastasis of NSCLC.

关键词

非小细胞肺癌 / 溶血磷脂酰胆碱酰基转移酶1 / 胞质多聚腺苷酸化结合蛋白1 / 复发转移 / 预测价值

Key words

non-small cell lung cancer / lysophosphatidylcholine acyltransferase 1 / cytoplasmic polyadenylationelementbinding protein 1 / recurrence and metastasis / predictive value

[1] 严洁,王裕虎. 血清微管解聚蛋白、CHI3L1与非小细胞肺癌患者肺癌根治术后复发转移的关系[J]. 检验医学与临床,2024,21(8):1054-1058.
[2] 杨馨雅,周悦思,韩英伦. 脂质代谢异常与癌症:诊断与治疗前景[J]. 中国细胞生物学学报,2024,46(12):2105-2116.
[3] 郭艳玲,张保祯,宝莹娜. LPCAT1在恶性肿瘤中的研究进展[J]. 内蒙古医科大学学报,2023,45(1):91-94,100.
[4] Xuan F, Ren Y, Lu J, et al.CPEB1 induces autophagy and promotes apoptosis in ovarian granulosa cells of polycystic ovary syndrome[J]. Mol Reprod Dev, 2024, 91(4): 1-14.
[5] 张新燕,赵国栋. miR-891a-5p通过CPEB1调控结肠癌细胞生物过程的机制研究[J]. 天津医药,2023,51(1):14-19.
[6] 中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志,2021,43(6):591-621.
[7] 何建行,梁文华. 基于分子标志的非小细胞肺癌术后复发预测专家共识[J]. 中国肺癌杂志,2022,25(10):701-714.
[8] 饶德新,潘丽红,刘恒,等. 血清miR-134-5p和趋化因子20对非小细胞肺癌患者肺癌根治术后复发转移的预测价值[J]. 中华实用诊断与治疗杂志,2022,36(2):130-135.
[9] 时春丽,周桂华,陈炜,等. 基于β-catenin/Slug信号通路表达探讨LPCAT1对子宫颈癌生物学行为的影响[J]. 临床与实验病理学杂志,2024,40(3):285-290.
[10] Xu J, Zhang Y, Chen H, et al.Up-regulation of LPCAT1 is correlated with poor prognosis and promotes tumor progression in glioblastoma[J]. Cytotechnology, 2024, 76(6): 735-748.
[11] Sun Q, Fu C, Liu J, et al.Knockdown of LPCAT1 Repressed Hepatocellular Carcinoma Growth and Invasion by Targeting S100A11[J]. Ann Clin Lab Sci, 2023, 53(2): 212-221.
[12] Huang Y, Wang Y, Wang Y, et al.LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways[J]. J Invest Dermatol, 2022, 142(2): 303-313.
[13] 刘小小,陈秀红,吕梦,等. 非小细胞肺癌组织中溶血卵磷脂胆碱酰基转移酶1表达与临床病理特征及预后的关系[J]. 中华实用诊断与治疗杂志,2021,35(6):572-575.
[14] 郭利佩,张群昌,曹馨,等. CPEB1通过抑制上皮间质转化逆转卵巢癌细胞化疗耐药的研究[J]. 生物技术进展,2026,16(1):205-212.
[15] 张驰,常海钰,王鑫. 乳腺癌组织CPEB1、USP11表达及其与临床病理参数和预后的关系[J]. 中国优生与遗传杂志,2025,33(7):1583-1588.
[16] Wang G, Ji X, Li P, et al.Human bone marrow mesenchymal stem cell-derived exosomes containing microRNA-425 promote migration, invasion and lung metastasis by down-regulating CPEB1[J]. Regen Ther, 2022, 25(20): 107-116.
[17] 黄祥,魏丹丹,王云,等. 非小细胞肺癌组织中miR-454-3p、CPEB1 mRNA表达水平及临床意义[J]. 疑难病杂志,2021,20(9):909-913.